Bio-Techne
TECH
556 hedge funds and large institutions have $16.2B invested in Bio-Techne in 2022 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 199 increasing their positions, 209 reducing their positions, and 76 closing their positions.
269% more call options, than puts
Call options by funds: $30.2M | Put options by funds: $8.18M
8.03% more ownership
Funds ownership: 376.15% → 384.18% (+8%)
5% less repeat investments, than reductions
Existing positions increased: 199 | Existing positions reduced: 209
3% less funds holding
Funds holding: 575 → 556 (-19)
14% less first-time investments, than exits
New positions opened: 65 | Existing positions closed: 76
15% less capital invested
Capital invested by funds: $19.1B → $16.2B (-$2.9B)
20% less funds holding in top 10
Funds holding in top 10: 15 → 12 (-3)
Top Buyers
Top Sellers
| 1 |
Marshall Wace
London,
United Kingdom
|
-$125M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$75.1M |
| 3 |
FAM
Fred Alger Management
New York
|
-$55.3M |
| 4 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$52.7M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$52.3M |
TECH Hedge Fund Activity: Q1 2022 in Review
556 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Bio-Techne (TECH) for Q1 2022, worth a combined $16.2B — down 15% from $19.1B a quarter earlier.
Sellers outnumbered buyers: 76 funds closed out of TECH and 65 opened new positions — a net loss of 11 holders — while 209 trimmed existing stakes and 199 added.
The largest buyer was Select Equity Group, opening a new position worth an estimated $288M. The largest seller was Marshall Wace, cutting an estimated $125M.
- 556 institutional investors held Bio-Techne (TECH) as of Q1 2022, down from 575 in Q4 2021.
- Funds reported $16.2B of Bio-Techne stock for Q1 2022, down 15% quarter-over-quarter.
- 65 funds opened new Bio-Techne positions in Q1 2022 and 76 closed out, a net change of -11 holders.
- The largest Bio-Techne buyer in Q1 2022 was Select Equity Group, an estimated $288M added.
- The largest Bio-Techne seller in Q1 2022 was Marshall Wace, an estimated $125M sold.
Based on aggregated 13F filings for Q1 2022.